BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1296 related articles for article (PubMed ID: 28356132)

  • 21. Valproic acid (VPA) inhibits the epithelial-mesenchymal transition in prostate carcinoma via the dual suppression of SMAD4.
    Lan X; Lu G; Yuan C; Mao S; Jiang W; Chen Y; Jin X; Xia Q
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):177-85. PubMed ID: 26206483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ZNF692 promotes cell proliferation, invasion and migration of human prostate cancer cells by targeting the EMT signaling pathway.
    Chen H; Li Y; Wu G; Zeng Q; Huang H; Zhang G
    Eur J Med Res; 2024 Jan; 29(1):88. PubMed ID: 38291502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serine protease inhibitor Kazal type 1 promotes epithelial-mesenchymal transition through EGFR signaling pathway in prostate cancer.
    Wang C; Wang L; Su B; Lu N; Song J; Yang X; Fu W; Tan W; Han B
    Prostate; 2014 May; 74(7):689-701. PubMed ID: 24619958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Up-regulation of TIF1γ by valproic acid inhibits the epithelial mesenchymal transition in prostate carcinoma through TGF-β/Smad signaling pathway.
    Qi G; Lu G; Yu J; Zhao Y; Wang C; Zhang H; Xia Q
    Eur J Pharmacol; 2019 Oct; 860():172551. PubMed ID: 31323225
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Notch-4 silencing inhibits prostate cancer growth and EMT via the NF-κB pathway.
    Zhang J; Kuang Y; Wang Y; Xu Q; Ren Q
    Apoptosis; 2017 Jun; 22(6):877-884. PubMed ID: 28374086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypoxia regulates ANXA1 expression to support prostate cancer cell invasion and aggressiveness.
    Bizzarro V; Belvedere R; Migliaro V; Romano E; Parente L; Petrella A
    Cell Adh Migr; 2017 May; 11(3):247-260. PubMed ID: 27834582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Slug contributes to cadherin switch and malignant progression in muscle-invasive bladder cancer development.
    Wu K; Zeng J; Zhou J; Fan J; Chen Y; Wang Z; Zhang T; Wang X; He D
    Urol Oncol; 2013 Nov; 31(8):1751-60. PubMed ID: 22421353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer.
    Jacob S; Nayak S; Fernandes G; Barai RS; Menon S; Chaudhari UK; Kholkute SD; Sachdeva G
    Endocr Relat Cancer; 2014 Jun; 21(3):473-86. PubMed ID: 24812058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines.
    Takeda M; Mizokami A; Mamiya K; Li YQ; Zhang J; Keller ET; Namiki M
    Prostate; 2007 Jun; 67(9):955-67. PubMed ID: 17440963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trichostatin A, a histone deacetylase inhibitor, reverses epithelial-mesenchymal transition in colorectal cancer SW480 and prostate cancer PC3 cells.
    Wang X; Xu J; Wang H; Wu L; Yuan W; Du J; Cai S
    Biochem Biophys Res Commun; 2015 Jan; 456(1):320-6. PubMed ID: 25434997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CX3CL1 increases invasiveness and metastasis by promoting epithelial-to-mesenchymal transition through the TACE/TGF-α/EGFR pathway in hypoxic androgen-independent prostate cancer cells.
    Tang J; Xiao L; Cui R; Li D; Zheng X; Zhu L; Sun H; Pan Y; Du Y; Yu X
    Oncol Rep; 2016 Feb; 35(2):1153-62. PubMed ID: 26718770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CAV-1 contributes to bladder cancer progression by inducing epithelial-to-mesenchymal transition.
    Liang W; Hao Z; Han JL; Zhu DJ; Jin ZF; Xie WL
    Urol Oncol; 2014 Aug; 32(6):855-63. PubMed ID: 24968949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. γ-Secretase inhibitor inhibits bladder cancer cell drug resistance and invasion by reducing epithelial-mesenchymal transition.
    Wang Y; Wang G; Zhang X; Zhou X; Liu Z; Huang L; Liu R; Lang B; Xu X; Liu W; Fu L; Fu B
    Mol Med Rep; 2015 Aug; 12(2):2821-7. PubMed ID: 25955824
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The CCL2-CCR2 Axis Contributes to Migration of Cabazitaxel-resistant Prostate Cancer Cells.
    Natsagdorj A; Izumi K; Hiratsuka K; Naito R; Kadomoto S; Iwamoto H; Yaegashi H; Shigehara K; Nakata H; Mizokami A
    Anticancer Res; 2023 Jun; 43(6):2561-2569. PubMed ID: 37247914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human chorionic gonadotropin beta (HCGbeta) down-regulates E-cadherin and promotes human prostate carcinoma cell migration and invasion.
    Wu W; Walker AM
    Cancer; 2006 Jan; 106(1):68-78. PubMed ID: 16323172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of SIRT1 Gene on Epithelial-Mesenchymal Transition of Human Prostate Cancer PC-3 Cells.
    Cui Y; Li J; Zheng F; Ouyang Y; Chen X; Zhang L; Chen Y; Wang L; Mu S; Zhang H
    Med Sci Monit; 2016 Feb; 22():380-6. PubMed ID: 26847404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer.
    Liu Z; Zhu G; Getzenberg RH; Veltri RW
    J Cell Biochem; 2015 Jul; 116(7):1341-9. PubMed ID: 25640606
    [TBL] [Abstract][Full Text] [Related]  

  • 38. N-cadherin promotes epithelial-mesenchymal transition and cancer stem cell-like traits via ErbB signaling in prostate cancer cells.
    Wang M; Ren D; Guo W; Huang S; Wang Z; Li Q; Du H; Song L; Peng X
    Int J Oncol; 2016 Feb; 48(2):595-606. PubMed ID: 26647992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cathepsin L upregulation-induced EMT phenotype is associated with the acquisition of cisplatin or paclitaxel resistance in A549 cells.
    Han ML; Zhao YF; Tan CH; Xiong YJ; Wang WJ; Wu F; Fei Y; Wang L; Liang ZQ
    Acta Pharmacol Sin; 2016 Dec; 37(12):1606-1622. PubMed ID: 27840408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PARP1-siRNA suppresses human prostate cancer cell growth and progression.
    Lai Y; Kong Z; Zeng T; Xu S; Duan X; Li S; Cai C; Zhao Z; Wu W
    Oncol Rep; 2018 Apr; 39(4):1901-1909. PubMed ID: 29393407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 65.